An Ontario-led international clinical trial has determined a new standard of care for patients with localized prostate cancer.
Browsing: Disease Area > Prostate
New investigation highlights preclinical efficacy of at combination of immune checkpoint inhibitors and therapies targeting myeloid-derived suppressor cells in advanced prostate cancer.
The goal of this study from Future Science OA is to utilize a novel strategy that combines biological outputs with Bayesian network learning to identify potential biomarkers for prostate cancer.
James Gulley of the National Cancer Institute talks to us about his work developing cancer immunotherapies, his insights into the impact of this modality in prostate cancer and his hopes for the future of the field.
Researchers document the first in-human application of a novel PET radiotracer.
Researchers have uncovered genetic markers that account for natural variation in the levels of prostate-specific antigen among men; these findings could improve accuracy when screening for prostate cancer.
A team has demonstrated how a prostate specific antigen nadir could be utilized to identify men at high-risk of early death as to provide more aggressive therapy.
Preclinical investigations suggest that a marker found on the surface of prostate cancer cells – NAALADL2 – could be targeted to potentially halt cancer growth.
Researchers have demonstrated that a hormone supplement, routinely used in prostate cancer patients following radiotherapy, may increase the chances of the cancer returning.